Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

Highest Quality | For Research Use Only

PT-141 Peptide

Synthetic peptide PT-141, also known as Bremelanotide, is primarily utilized in the treatment of sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). This peptide is a melanocortin receptor agonist, specifically binding to the MC3 and MC4 receptors, which are known to regulate sexual behavior.

The mechanism of PT-141’s action is unique when compared to other erectile dysfunction or sexual arousal medications. Instead of acting on the vascular system like Viagra, PT-141 operates directly on the nervous system by increasing the level of dopamine—a neurotransmitter that plays a key role in the regulation of sexual behavior. It’s this distinctive mode of action that allows PT-141 to be effective in treating sexual disorders related to psychological and physical issues.

Showing all 4 results

Potential Benefits of PT-141 Peptide

  • Sexual Dysfunction Treatment: PT-141 research has demonstrated efficacy in the treatment of sexual dysfunction in both men, specifically for erectile dysfunction, and women, particularly for sexual arousal disorder. This mechanism of action involves the activation of melanocortin receptors within the brain, resulting in the augmentation of sexual arousal [1] and [2].
  • FDA Approved: The U.S. Food and Drug Administration (FDA) has approved PT-141 for the treatment of premenopausal women with hypoactive sexual desire disorder [3].
  • Central Nervous System Mechanism: According to research, unlike other sexual dysfunction drugs that work at the vascular level, PT-141 operates at the level of the central nervous system, potentially providing a more targeted treatment [4].

References

[1] https://www.sciencedirect.com/science/ article/abs/pii/S0196978105004602

[2] https://academic.oup.com/jsm/ article-abstract/3/4/628/6882956

[3] https://www.fda.gov/news-events/ press-announcements/ fda approves new treatment hypoactive sexual desire disorder premenopausal women

[4] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC8788464/

DISCLAIMER: We do not supply peptides to any individual under the age of 21. You must be a licensed and qualified healthcare practitioner. Our team of dedicated professionals are committed to providing an extensive range of products used ONLY in the process of laboratory research by responsible trained and professional individuals. All products listed on this website (https://direct-peptides.com) and provided through Direct Peptides are intended for laboratory research purposes only. The products listed on this website are NOT for human or animal consumption or ingestion of any kind.